Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
Table 1 Demographics and disease characteristics in patients developing acute or chronic GVHD (with and without TA-TMA) post-alloHSCT. Full size table All pathology material was initially evaluated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results